Active Ingredient History
Lactiplantibacillus plantarum is a widespread member of the genus Lactiplantibacillus and commonly found in many fermented food products as well as anaerobic plant matter. L. plantarum was first isolated from saliva. Based on its ability to temporarily persist in plants, the insect intestine and in the intestinal tract of vertebrate animals, it was designated as a nomadic organism. L. plantarum is Gram positive, bacilli shaped bacterium. L. plantarum cells are rods with rounded ends, straight, generally 0.9–1.2 μm wide and 3–8 μm long, occurring singly, in pairs or in short chains. L. plantarum has one of the largest genomes known among the lactic acid bacteria and is a very flexible and versatile species. It is estimated to grow between pH 3.4 and 8.8. Lactiplantibacillus plantarum can grow in the temperature range 12 °C to 40 °C. The viable counts of the "L. plantarum" stored at refrigerated condition (4 °C) remained high, while a considerable reduction in the counts was observed stored at room temperature. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 2/Phase 3)
Adenomatous Polyposis Coli (Phase 2)
Aged (Early Phase 1)
Anxiety Disorders (Phase 2)
Ascites (Phase 2)
Asthma (Phase 1/Phase 2)
Bacterial Infections (Phase 1)
Celiac Disease (Phase 4)
Cognitive Dysfunction (Phase 4)
Colic (Phase 4)
Colonoscopy (Phase 2)
Constipation (Phase 2/Phase 3)
Coronary Artery Disease (Phase 4)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 2)
Crohn Disease (Phase 4)
Deglutition Disorders (Early Phase 1)
Depression (Phase 4)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Diarrhea (Phase 4)
Drug Resistance, Bacterial (Phase 2)
Esophageal and Gastric Varices (Phase 3)
Fatty Liver (Phase 1)
Fibrosis (Phase 4)
Gastroenteritis (Phase 4)
Gastrointestinal Microbiome (Phase 2)
General Surgery (Phase 3)
Healthy Volunteers (Phase 1)
Helicobacter pylori (Phase 2)
Hematopoiesis (Phase 1)
Hepatic Encephalopathy (Phase 4)
Hirschsprung Disease (Phase 2)
Hypersensitivity (Phase 4)
Hypertriglyceridemia (Phase 3)
Inflammation (Phase 2)
Inflammatory Bowel Diseases (Phase 3)
Interleukin-17 (Phase 1/Phase 2)
Intestinal Neoplasms (Early Phase 1)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Phase 2)
Klebsiella pneumoniae (Phase 1/Phase 2)
Leukemia (Phase 3)
Liver Cirrhosis (Phase 2/Phase 3)
Lymphoma (Phase 3)
Metabolic Syndrome (Phase 2)
Multiple Myeloma (Phase 3)
Neoplasms (Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 1/Phase 2)
Osteoporosis (Phase 2)
Overweight (Phase 3)
Peritonitis (Phase 2/Phase 3)
Pneumonia, Viral (Phase 2)
Polycystic Ovary Syndrome (Phase 3)
Probiotics (Phase 4)
Psoriasis (Phase 1/Phase 2)
Scleroderma, Systemic (Phase 2)
Sepsis (Phase 2)
Vaginal Diseases (Phase 1)
Vaginitis (Phase 1)
Vaginosis, Bacterial (Phase 1)
Volunteers (Phase 4)
Weight Loss (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
